[HTML] nature.com

[HTML][HTML] Cas13d knockdown of lung protease Ctsl prevents and treats SARS-CoV-2 infection

Z Cui, C Zeng, F Huang, F Yuan, J Yan, Y Zhao… - Nature chemical …, 2022 - nature.com
SARS-CoV-2 entry into cells requires specific host proteases; however, no successful in vivo
applications of host protease inhibitors have yet been reported for treatment of SARS-CoV-2 …
被引用次数：34 相关文章

Cas13d knockdown of lung protease Ctsl prevents and treats SARS-CoV-2 infection

Z Cui, C Zeng, F Huang, F Yuan… - Nature Chemical …, 2022 - ohiostate.elsevierpure.com
SARS-CoV-2 entry into cells requires specific host proteases; however, no successful in vivo
applications of host protease inhibitors have yet been reported for treatment of SARS-CoV-2 …

Cas13d knockdown of lung protease Ctsl prevents and treats SARS-CoV-2 infection.

Z Cui, C Zeng, F Huang, F Yuan, J Yan… - Nature Chemical …, 2022 - europepmc.org
SARS-CoV-2 entry into cells requires specific host proteases; however, no successful in vivo
applications of host protease inhibitors have yet been reported for treatment of SARS-CoV-2 …

Cas13d knockdown of lung protease Ctsl prevents and treats SARS-CoV-2 infection

Z Cui, C Zeng, F Huang, F Yuan… - Nature chemical …, 2022 - pubmed.ncbi.nlm.nih.gov
SARS-CoV-2 entry into cells requires specific host proteases; however, no successful in vivo
applications of host protease inhibitors have yet been reported for treatment of SARS-CoV-2 …
[HTML] nih.gov

[HTML][HTML] Cas13d knockdown of lung protease Ctsl prevents and treats SARS-CoV-2 infection

Z Cui, C Zeng, F Huang, F Yuan, J Yan… - Nature chemical …, 2022 - ncbi.nlm.nih.gov
SARS-CoV-2 entry into cells requires specific host proteases; however, no successful in vivo
applications of host protease inhibitors have yet been reported for treatment of SARS-CoV-2 …